APA

Jacobs M. S., de Jong L. A., Postma M. J., Tieleman R. G. & van Hulst M. (20180827). Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation. : The European journal of health economics : HEPAC : health economics in prevention and care.

Chicago

Jacobs Maartje S, de Jong Lisa A, Postma Maarten J, Tieleman Robert G and van Hulst Marinus. 20180827. Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation. : The European journal of health economics : HEPAC : health economics in prevention and care.

Harvard

Jacobs M. S., de Jong L. A., Postma M. J., Tieleman R. G. and van Hulst M. (20180827). Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation. : The European journal of health economics : HEPAC : health economics in prevention and care.

MLA

Jacobs Maartje S, de Jong Lisa A, Postma Maarten J, Tieleman Robert G and van Hulst Marinus. Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation. : The European journal of health economics : HEPAC : health economics in prevention and care. 20180827.